Cannabidiol

Contraindicated

Cannabidiol Deuruxolitinib Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details

Major

Cannabidiol Acetaminophen And Codeine Capital® & Codeine Explained Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Omeprazole Gastrobim Explained Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Cannabidiol Buprenorphine Belbuca Explained Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Abrocitinib Cibinqo Explained Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Cannabidiol Aripiprazole Injection Abilify Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Asenapine Transdermal Patch Secuado Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Butorphanol Injection Butorphic Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Butorphanol Nasal Spray Stadol® NS Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Cetirizine Injection Aller-Tec Increased risk of CNS depression Details Cannabidiol Cetirizine Ophthalmic Zerviate Increased risk of CNS depression Details Cannabidiol Cyclophosphamide Cytoxan® Altered (increased or reduced) CYP2B6 substrates exposure Details Cannabidiol Cyclophosphamide Injection Cytoxan® Injection Altered (increased or reduced) CYP2B6 substrates exposure Details Cannabidiol Dapagliflozin Farxiga Increased UGT1A9 substrate exposure and an increased risk of UGT1A9 substrate-related adverse reactions Details Cannabidiol Daprodustat Jesduvroq Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse reactions Details Cannabidiol Desloratadine Clarinex Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse reactions Details Cannabidiol Dexlansoprazole Dexilant Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Cannabidiol Diazepam Nasal Spray Valtoco Increased CYP2C19 substrate exposure, an increased risk of CYP2C19 substrate-related adverse reactions, an increased risk of CNS d... Details Cannabidiol Diazepam Rectal Diastat Increased CYP2C19 substrate exposure, an increased risk of CYP2C19 substrate-related adverse reactions, an increased risk of CNS d... Details Cannabidiol Digoxin Cardoxin® Increased P-gp substrate exposure Details Cannabidiol Diphenhydramine Injection Banophen Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Diphenhydramine Topical Afterbite with Antihistamine Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Encorafenib Braftovi Reduced exposure of cannabidiol and reduced active cannabidiol metabolite exposure Details Cannabidiol Erdafitinib Balversa Increased erdafitinib exposure Details Cannabidiol Ertugliflozin Steglatro Increased UGT1A9 substrate exposure and an increased risk of UGT1A9 substrate-related adverse reactions Details Cannabidiol Esketamine Nasal Spray Spravato Altered (increased or reduced) esketamine exposure, an increased risk of CNS depression and an increased risk of sedation and somn... Details Cannabidiol Esomeprazole Nexium Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Cannabidiol Esomeprazole Injection Nexium Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Cannabidiol Everolimus Afinitor Increased everolimus exposure Details Cannabidiol Fentanyl Transdermal Patch Duragesic® Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Hydromorphone Injection Dilaudid Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Hydromorphone Rectal available generically Increased risk of CNS depression and an increased risk of sedation and somnolence Details Cannabidiol Hydroxychloroquine Plaquenil Impaired antiepileptic activity Details Cannabidiol Ifosfamide Injection Ifex Altered (increased or reduced) CYP2B6 substrates exposure Details Cannabidiol Labetalol Normodyne® Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Cannabidiol Lacosamide Injection Motpoly Increased CYP2C19 substrate exposure, an increased risk of CYP2C19 substrate-related adverse reactions, increased risk of CNS depr... Details Cannabidiol Lansoprazole Prevacid Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Cannabidiol Letermovir Injection Prevymis Reduced active cannabidiol metabolite exposure and an altered cannabidiol exposure Details Cannabidiol Levodopa Oral Inhalation Inbrija An increased risk of CNS depression Details Cannabidiol Loperamide Diamode Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse reactions Details